2024 Revenues ($USD) : $7.74B

Chugai Pharmaceutical, the research-focused arm of the Roche Group based in Tokyo, put up some strong numbers for 2024. Revenues climbed 5.3% year-on-year to ¥1,170.6 billion (that's around $8.7 billion USD). Even better, operating profit surged 23.4% and net income grew a healthy 19.0%.

What fueled this? New products like Phesgo and Vabysmo started chipping in, while mainstays Hemlibra and Actemra kept performing. Overseas sales looked particularly strong, getting a nice boost from Hemlibra exports heading to Roche. Operationally, Chugai managed to significantly trim its cost-to-sales ratio while still upping its R&D investment to ¥176.9 billion (an 8.7% increase).

Looking ahead to 2025, the forecast is a bit more subdued. Chugai is projecting revenue growth of just 1.7% to ¥1,190.0 billion. The expectation is for domestic sales to barely edge up (0.3%), facing headwinds from drug price cuts and generic competition, even with support from new and existing products. Overseas sales are seen doing better, with a 3.5% increase anticipated, driven by Hemlibra, Alecensa, and NEMLUVIO.

Strategically, the company says it's focused on shifting resources towards research and early development (RED), using digital tools (DX) to spur innovation and efficiency, and leaning into open innovation partnerships.

From an analyst's chair, Chugai's 2024 looks good – strong profit growth, good cost control, and continued commitment to R&D. Key things to watch now are how those new and established products, especially Hemlibra, perform, and how well Chugai navigates the pricing pressures and generic threats in Japan, which likely explain that conservative 2025 outlook. Ultimately, the success of its strategic moves (RED, DX, Open Innovation) will be key to turning that R&D spend into commercial wins and keeping growth going despite the market challenges.